Navigation Links
New Cardiac Electrical Biomarker Featured In Johns Hopkins Abstract Demonstrates Strong Correlation To High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury
Date:3/25/2013

TOTOWA, N.J., and SAN FRANCISCO, March 25, 2013 /PRNewswire/ -- From the 2013 American College of Cardiology (ACC) Convention

One of the leading complaints in the Emergency Department is chest pain and the timely detection of a heart attack is essential. Because of this, VectraCor, Inc., an emerging medical device company for cardiovascular solutions, is pleased to announce that The Johns Hopkins Hospital presented an abstract at the ACC conference in San Francisco that utilized their VectraplexECG System. The abstract, entitled New Cardiac Electrical Biomarker Measured on 12-Lead ECG Strongly Correlates with High Sensitivity Troponin in Patients Admitted to the Emergency Department to Rule Out Acute Myocardial Ischemic Injury, was presented by  Dr. Larisa Tereshchenko , M.D., Ph.D., FAHA, of The Johns Hopkins Hospital.  

The VectraplexECG System incorporates a novel biomarker, the Cardiac Electrical Biomarker™ (CEB™), which in real-time, detects ECG changes suggestive of an Acute Myocardial Infarction (AMI/Heart Attack). The CEB™ is an easy-to-read index number that will continuously display as the patient is monitored, potentially leading to faster treatment and clinician intervention for patients in the Emergency Department.

Data was analyzed on 130 patients, participants of a prospective cohort study, admitted to the emergency department (ED) to rule out acute myocardial infarction. Overall, 475 ECGs and 489 High Sensitivity Troponin (HST) measurements were included in the analysis. The CEB™ showed a strong, positive correlation with (HST) (r=0.560; P=0.0007).

"VectraCor is very excited about the data Johns Hopkins has presented and that our CEB™ shows a strong correlation to High Sensitivity Troponin," said Brad S. Schreck , President & CEO of VectraCor. He added, "Our technology is an exciting, non-invasive, real-time technology that will benefit many patients and may help clinicians diagnose more quickly the #1 disease in the world."

"In this study we ran a completely blinded analysis of electrocardiograms. The strong correlation between VectraCor's CEB™ and troponin in a multivariate analysis (after adjustment for other clinical and demographic characteristics of patients) was very impressive. Future use of the VectraplexECG System with CEB holds big promise", stated Dr. Larisa Tereshchenko .  

The current "gold standard" for AMI detection is a long process which can continue up to 24 hours and involves placing 10 electrodes to produce a 12-lead ECG and measuring cardiac serum biomarkers (i.e. troponin) every 3-6 hours via invasive blood draws. The VectraplexECG System (FDA-cleared/CE Marked) uses only 5 electrodes to detect ECG changes suggestive of AMI and derives a 15-lead ECG (US) and the 22-lead ECG (EU). This will give the clinician more information with fewer electrodes, while potentially reducing lead placement error.

About VectraCor
VectraCor is a New Jersey-based medical device company with disruptive technology in the cardiovascular and emergency markets. This unique technology has the potential to become the new standard of care in cardiac monitoring. Visit us at www.vectracor.com or 973-904-0444.

MEDIA CONTACT:
MICHAEL VAN LAAR
VectraCor, Inc.
973.904.0444
mvanlaar@vectracor.com


'/>"/>
SOURCE VectraCor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
2. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
3. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
4. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
5. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
6. Cardiac Science to Supply Q-Tel Data to AACVPR Cardiac Rehabilitation Registry
7. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
8. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
9. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
10. Markets for Electrostimulation Devices (Neurostimulation, Cardiac Rhythm Management, Fracture Healing and Others)
11. Cardiac Science Earns Top Marks for Cardiac Stress Test, Telemetry Monitor Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/29/2017)... Orion, Michigan (PRWEB) , ... April 29, 2017 ... ... signs of fertility and infertility. These methods observe the naturally occurring signs ... in intercourse during the most fertile time. , Natural family planning and ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission ... Home Care Association of America (HCAOA). This agreement allows HCAOA members to receive ... well as discounts on Accreditation University (AU) educational resources that help prepare HCAOA ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield ... credit rating of “A” and its outlook as “stable.” At the same time, the ... have fallen in recent years, dip below “capital adequacy” thresholds required for its strong ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):